Latest Breaking News On - John nicols - Page 4 : comparemela.com

Codexis Announces CEO Transition Effective August 9, 2022

Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEOJohn Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY,. | July 18, 2022

Smithkline-beecham
Byron-dorgan
Carrie-mckim
John-nicols
Glaxosmithkline
Genentech
Nasdaq
Exchange-commission
University-of-london
Sierra-oncology-inc
Nestle-health-science

Codexis (CDXS) Prelim. Q2 Results Miss Consensus

Codexis (CDXS) Prelim. Q2 Results Miss Consensus
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

John-nicols
Pfizer
Codexis-inc
Nasdaq

Codexis (CDXS) Enters Agreement with Pfizer to Supply Enzyme for the Manufacture of PAXLOVID

Codexis (CDXS) Enters Agreement with Pfizer to Supply Enzyme for the Manufacture of PAXLOVID
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Pamela-siwik
Carrie-mckim
John-nicols
Pfizer
Exchange-commission
Drug-administration
Codexis-inc
Nasdaq
Wall-street
Vice-president
Launch-excellence

Codexis Reports First Quarter 2022 Financial Results

Codexis Reports First Quarter 2022 Financial Results
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United-states
American
Codexi-codeevolver
John-nicols
American-society-of-gene
Drug-administration
Codexis-inc
Key-customer-program
Nasdaq
Total-revenue
Product-revenue
Product-gross-margin-expands

Codexis Announces FDA Orphan Drug and Rare Pediatric Disease Designations for CDX 6512 for the Treatment of Homocystinuria

24.01.2022 - REDWOOD CITY, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) - Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted the . Seite 1

United-states
John-nicols
International-congress
Drug-administration
Codexis-inc
Nasdaq
Inborn-errors